Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 26;10(2):274. doi: 10.3390/biomedicines10020274

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

An overview of the current drug development pipeline for non-alcoholic fatty liver disease. FASN, fatty acid synthase; DGAT, diglyceride acyltransferase; FXR, farnesoid X receptor; FGF, fibroblast growth factor; TLR4, toll-like receptor 4; LOXL2, lysyl oxidase-like protein 2; ATX, autotaxin; SGLT, sodium/glucose contransporter; MPC, mitochondrial pyruvate carrier; PPAR, peroxisome proliferator-activated receptor; THRβ, thyroid hormone receptor β; PUFA, polyunsaturated fatty acid; ACC, acetyl-CoA carboxylase; BUDCA, berberine ursodeoxycholate; LMS, leucine-metformin-sildenafil; LMSC, liver-derived mesenchymal stromal cells.